human health biotechnologies to 2015
TRANSCRIPT
0.5 2 3 3 4 4.5 3.5 1 1
10.5
1 3 11.5
6
100.5
0
20
40
60
80
100
120
Australia
Canada
China
Cuba
Denmark
France
Germany
Ireland
Israel
Japan
Netherla
nds
South Korea
Switzerla
nd UK
USA
20
30
40
50
60
70
80
90
100
1991 1992
1993 1994
1995 1996
1997 1998
1999 2000
2001 2002
2003 2004
2005 2006
2007 2008
0
20
40
60
80
100
120
140
160
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
140
194
52
7
106
156
39
9 12
22
3 2 0
20
40
60
80
100
120
140
160
180
200
Phase I Clinical Trial Phase II Clinical Trial Phase III Clinical Trial Pre-registration
USA
Other OECD
Non OECD
0
2
4
6
8
10
12
2008 2009
2010 2011
2012 2013
2014 2015
2016 2017
2018
Therapeutics
Vaccines
Other
0
5
10
15
20
25
1989 1990
1991 1992
1993 1994
1995 1996
1997 1998
1999 2000
2001 2002
2003 2004
2005 2006
2007 2008
2009 2010
2011 2012
2013 2014
2015
0
200
400
600
800
1 000
1 200
1 400
1 600
1 800
1993 1994
1995 1996
1997 1998
1999 2000
2001 2002
2003 2004
2005 2006
2007 2008
0
10
20
30
40
50
60
70
80
90
100
1998 1999
2000 2001
2002 2003
2004 2005
2006 2007
2008
INSD Total
GenBank + USPTO
EMBL + EPO
DDBJ + JPO + KIPO
Clinical Outcome 12%
Pharmacodynamics & Drug Responses
20%
Pharmacokinetics 16%
Molecular & Cellular Functional Assays
26%
Genotype 26%
0
100
200
300
400
500
600
1990 1991
1992 1993
1994 1995
1996 1997
1998 1999
2000 2001
2002 2003
2004 2005
2006 2007
0
10
20
30
40
50
60
70
80
1960-1969 1970-1979 1980-1989 1990-1999 2000-2007
Journal of the American Medical Association
0
1000
2000
3000
4000
5000
1960-1969 1970-1979 1980-1989 1990-1999 2000-2007
PubMed
0%
5%
10%
15%
20%
25%
30%
35%
40%
1990 1995 2000 2005
